DOCSLIB.ORG

Pharmacy & Poisons Act Cap

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LAWS OF FIJI REVISED 1985 CHAPTER 115 ______ PHARMACY AND POISONS ______ TABLE OF PROVISIONS ______ PART I - PRELIMINARY SECTION 1. Short title 2. Interpretation 2A. Meaning of "medicine" and related expressions 2B. Certain substances or articles to be treated as medicines 3. Meaning of "sale" 4. Meaning of "adulteration" PART II - ADMINISTRATION 5. The Pharmacy and Poisons Board 6. Members of Board 7. Meetings of the Board 8. Board may summon person to attend and give evidence 9. Chairman may administer oath 10. Person failing to appear when summoned 11. Person refusing to make oath or affirmation 12. False testimony 13. Liability of members 14. Fees 15. Power of search 16. Secretary. Inspectors 17. Persons eligible for appointment as inspectors 18. Powers of inspectors 19. Certificate of Government analyst PART III - PHARMACISTS 20. Register of Pharmacists 21. Pharmacists how registered 22. Persons eligible for registration 23. Board may direct examination of applicant 24. Registration of applicants 25. Appeal against refusal of Board to register 26. Copy of register to be published 27. Fraudulent representation 28. Amendments may be made in register 29. Notification of change of address or death 30. Correction of register 31. Corporate body may carry on business of pharmacist 32. Restriction on number of pharmacies 32A. Establishment of Fiji Pharmaceutical Society 32B. Objects of Fiji Pharmaceutical Society 32C. Former Fiji Pharmaceutical Society PART IV - CONDUCT OF BUSINESS AS PHARMACIST 33. Grounds of cancellation of registration 34. Removal of name from register 35. Surrender of certificate of registration 36. Persons other than registered pharmacists not to carry on business 37. Death, unsoundness of mind or bankruptcy of pharmacist 38. Name of pharmacist to be exhibited 39. Pharmacists only to dispense 40. Temporary licence 41. Prescriptions to be signed 42. Record of prescriptions 43. Conduct of business by pharmacist 44. Medical practitioners, etc., may dispense 45. Automatic machines for vending medicines prohibited 46. Restrictions on supply of certain medicines 47. False or misleading advertisements 47A. Prohibition of certain advertisements 47B. Meaning of "advertisement" in sections 47 and 47A 48. British Pharmacopoeia PART V - MANUFACTURE, SALE AND SUPPLY OF MEDICINES 48A. Licensing of manufacture and wholesale dealing 48B. Exemptions from licensing 48C. Application for manufacturer's or wholesale licence 48D. Factors relevant to determination of application 48E. Persons qualified for grant of manufacturer's licences 48F. Grant or refusal of licence 48G. Duration and renewal of licence 48H. Suspension, variation and revocation of manufacturer's or wholesale licences 48I. Variation of manufacturer's or wholesale licence on application of holder 48J. Appeals 48K. Inspection and search of premises, etc. 48L. Offences 49. Sale of medicines 50. Medicine Licence 51. Animal Medicine Licence 52. Police to be notified of issue of licence 53. Only medicines mentioned in licence may be sold 54. (Repealed) 55. Adulteration of medicines 56. Sale of adulterated medicines 57. Offence in relation to sales 58. Reliance on written warranty a good defence 59. Importation of medicines 60. Labels on medicines imported 61. Importation of certain medicines may be prohibited PART VI - POISONS 62. Importation and sale of poisons 63. Pharmacists to be authorised sellers of poisons 64. Poisons Licence 65. Register of Premises 66. Prohibition and regulations with respect to the sale of poisons 67. Exemption with respect to medicines 68. Exemption with respect to certain sales 69. Use of titles, emblems and descriptions 70. Prohibition of sale of poisons by means of automatic machine PART VII - MISCELLANEOUS 71. Regulations 72. General penalty 73. Application of Customs law First Schedule-Countries, etc., Specified for the Purpose of Section 22 Second Schedule-Exempted Articles Third Schedule-The Poisons List Fourth Schedule-Animal Medicines __________ Ordinances Nos. 30 of 1937, 22 of 1938, Order in Council No. 4 of 1938, Ordinances Nos. 2 of 1945, 1 of 1951, 9 of 1955, Order 12 September 1957, Ordinance No. 5 of 1958, Order 31 March 1959, Ordinances Nos. 20 of 1960, 32 of 1962, Order 22 March 1965, Ordinances Nos. 37 of 1966, 52 of 1968, 11 of 1970, Legal Notices Nos. 112 of 1970, 118 of 1970, 58 of 1971, 104 of 1971, 59 of 1973, 28 of 1975, Acts Nos. 14 of 1975, 24 of 1976, Legal Notice No. 124 of 1977, Acts Nos. 2 of 1980, 18 of 1984, Legal Notices Nos. 155 of 1980, 180 of1980, 12 of 1981, 35 of 1983, 36 of 1983 AN ACT TO PROVIDE FOR THE REGISTRATION OF PHARMACISTS AND TO CONTROL THE PRACTICE OF PHARMACY AND THE SALE AND DISTRIBUTION OF DRUGS AND POISONS AND FOR PURPOSES CONSEQUENTIAL THEREON [1 January 1938] PART I - PRELIMINARY Short title 1. This Act may be cited as the Pharmacy and Poisons Act. Interpretation 2.-(1) In this Act, unless the context otherwise requires - "administer" in relation to any substance or article means administer it either in its existing state or after it has been dissolved or dispersed in, or diluted or mixed with, some other substance used as a vehicle; "assembly" in relation to a medicine, means the process of enclosing the medicine in a container which is labelled before the medicine is sold or offered for sale, or where the medicine is already enclosed in the container in which it is to be sold or offered for sale, labelling the container before the medicine is sold or offered for sale in it; "Board" means the Pharmacy and Poisons Board appointed under this Act; "chairman" means the chairman of the Board appointed under this Act; "manufacture" in relation to a medicine, includes any process carried out in the course of making the medicine including the assembly thereof, but does not include dissolving or dispersing the medicine in, or diluting or mixing it with, some other substance used as a vehicle for the purpose of administering it and does not include the incorporation of the medicine in any animal feeding stuff; "medicine" and "medicinal purpose" have the meanings assigned to them by section 2A; "member" means a member of the Board constituted under this Act; "Permanent Secretary" means the Permanent Secretary for Health; "poison" includes the several substances mentioned in the Poisons List in the Third Schedule; "qualified veterinary surgeon" means any veterinary surgeon registered under the provisions of the Veterinary Surgeons Act; (Cap. 257.) "register" means the Register of Pharmacists registered under this Act; "registered dentist" means a dentist registered under the Medical and Dental Practitioners Act; (Cap. 255.) "registered medical practitioner" or "medical practitioner" or "duly qualified practitioner" means a medical practitioner registered under the Medical and Dental Practitioners Act; (Cap. 255.) "registered pharmacist" means a person registered under the provisions of this Act. (Amended by Ordinance 5 of 1958, s. 2; 32 of 1962, s. 2; 37 of 1966, s. 39; Act 14 of 1975, s. 26; 2 of 1980, s. 2.) (2) In this Act any reference to selling anything by way of wholesale dealing is a reference to selling it to a person who buys it for the purpose of - (a) selling or supplying it; or (b) administering it or causing it to be administered to one or more human beings, in the course of a business carried on by that person, except that it does not include any such sale by the person who manufactured it under and in accordance with a manufacturer's licence. (Inserted by Act 2 of 1980, s. 2.) Meaning of "medicine" and related expressions 2A.-(1) In this Act - (a) "medicine" means any substance or article (not being an instrument, apparatus or appliance) which is manufactured, sold or offered for sale for use wholly or mainly in either or both of the following ways: (i) use by being administered to human beings or animals for a medicinal purpose; (ii) use, in circumstances specified in subsection (2), as an ingredient in the preparation of a substance or article which is to be administered to human beings or animals for a medicinal purpose, but, except as provided in section 2B, medicine does not include a substance or article the sole or principal use of which is, or ordinarily is, a cosmetic use, or which is represented to be, or might reasonably be taken to be, for cosmetic use; (b) "medicinal purpose" means any one or more of the following purposes: (i) treating or preventing a disease; (ii) diagnosing disease or ascertaining the existence, degree or extent of a physiological condition; (iii) contraception; (iv) inducing anaesthesia; (v) otherwise preventing or interfering with the normal operation of a physiological function, whether permanently or temporarily, and whether by way of terminating, reducing or postponing, or increasing or accelerating, the operation of that function or in any other way. (2) The circumstances referred to in subsection (1) (a) (ii) are - (a) use in a pharmacy or in a hospital, clinic, nursing home or similar institution; (b) use by a medical practitioner, registered dentist, registered pharmacist or a qualified veterinary surgeon; (c) use in the course of a business which consists of or includes the retail sale of herbal remedies. (3) In subsection (2)(c) "herbal remedy" means a medicine consisting of a substance produced by subjecting a plant to drying, crushing or any other process, or of a mixture whose sole ingredients are two or more substances so produced, or of a mixture whose sole ingredients are one or more substances so produced and water or some other inert substance. (Inserted by Act 2 of 1980, s. 3.) Certain substances or articles to be treated as medicines 2B.-(1) Where in the course of trade or business any substance or article is manufactured, sold or offered for sale as a medicine or is described as a medicine or recommended in any manner to be used for a medicinal purpose that substance or article shall be treated as a medicine for the purposes of this Act.
Recommended publications
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm

    Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm

    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
  • Postoperative Vomiting: a Review and Present Status of Treatment

    Postoperative Vomiting: a Review and Present Status of Treatment

    POSTOPERATIVE VOMITING: A REVIEW ~ND ~?RESENT STATUS OF TREATMENT* L. E. SI2vlONSEN, M.D., C.NI., and S. L. VANDEWAjTER,M.D., r.R.c.r. (c.) t POSTOPERATIVE VO~vlITING remains one of the most I frequent complications en- countered by the anaesthetist. Although considered no|more than a nuisance complication, it can, in certain cases, contribute to more ~lSan just discomfort for the patient; it can threaten his very life either immediately through aspiration, or later by serious loss bf fluids and electrolytes. It cap also add considerable strain on some operation wounds. After Wang and Boxison 1 further delineated the vomit ng centre in 1952, most of the succeeding research and investigation into the ~ontrol of vomiting has centred about those drugs that have a depressant actio 1 on the chemoreceptor trigger zone (C.T.Z.). Out of these investigations have c ~me much valuable and interesting data which the anaesthetist may use as additio ns to his ever-expanding resources to provide safety and comfort to the surgical patient. THE VOMXTn~OCENTaE Neurophysiologists have long accepted the existence of a vomiting centre. Located in the medulla in the solitary tract and the dgrsal part of the lateral reticular formation, it lies in close relationship to ma:ay other centres whose functions are associated with the vomiting act such ts salivation, spasmodic respiratory movements, and forced inspiration. ~ Lying lorsolateral to the vagal nuclei and close to the vomiting centre in the area pos :rema of thefloor of the fourth ventricle is an accessory vomiting centre which Ihas been designated as the C.T.Z.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Regulation Gazette, No. 8457

    Regulation Gazette, No. 8457

    STAATSKOERANT, 28 APRIL 2006 No. 28761 3 GOVERNMENT NOTICE GOEWERMENTSKENNISGEWING DEPARTMENT OF HEALTH DEPARTEMENT VAN GESONDHEID No. R. 394 28 April1 2006 FOODSTUFFS, COSMETICS AND DISNFECTANTS ACT, 1972 (ACT NO 54 OF 1972) REGULATIONS GOVERNING THE LABELLING] ADVERTISING AND COMPOSITION OF COSMETICS The Minister of health intends, in terms of section 15(1) of the foodstuffs, cosmetics and DisinfectadsAct, 1972 (Ad No 54 of 1972), to m&e the regulations in be Schedule. Interested persons are invited to submit any substantiated comments a repremtaticns on the propod regulations to the Director-General of Hedth, Private Bag X828, Pretoria, OOOl (for the &mlon of the Director: ~nspedorateand Law Enforcement, within three months of the date of publication of this notice. SCHEDULE I. DEFINITIONS In these regulatirns 'the Act' means the Foodstuffs, Cosmetic and Disinfectants Ad, 1972 (Ad No 54 of 1972) and any expression to which a meaning has been assigned in the Act shall bear such meaning and, unless inconsistent with the context - "address" means an address in the Republic of South Africa and the street or road number (if a nu& has be allotted), the name of the street or road and the name of the town, Village or suburb and, in the case of a farm, the name ofthe farm and of the magisterial dstrict in which it is situated and, in the case of impcrted cosmetics, "address' means the address of the importer or distributor in the Republic; "annex" means an annex to these regulations; "bulk stock container" means a container that contains more
  • 付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated

    付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated

    付表ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated Pharmaceutical Active Ingredients 号(Sub-heading) 品名 Description 2818.30 アルゲルドラート algeldrate 2833.22 アルスルフ alusulf 2842.10 アルマシラート almasilate 2842.10 シマルドラート simaldrate 2842.90 硫酸アルマドラ ート almadrate sulfate 2842.90 アルマガート almagate 2842.90 カルバルドラード carbaldrate 2842.90 ヒドロタルシト hydrotalcite 2842.90 マガルドラート magaldrate 2843.30 オーラノフィン auranofin 2843.30 金チオグリカニド aurothioglycanide 2843.30 金チオりんご酸ナトリウム sodium aurothiomalate 2843.30 金チオ硫酸ナトリウム sodium aurotiosulfate 2843.90 カルボプラチン carboplatin 2843.90 シスプラチン cisplatin 2843.90 デキソルマプラチン dexormaplatin 2843.90 エンロプラチン enloplatin 2843.90 イプロプラチン iproplatin 2843.90 ロバプラチン lobaplatin 2843.90 ミボプラチン miboplatin 2843.90 ネダプラチン nedaplatin 2843.90 オルマプラチン ormaplatin 2843.90 オキサリプラチン oxaliplatin 2843.90 セブリプラチン sebriplatin 2843.90 スピロプラチン spiroplatin 2843.90 ゼニプラチン zeniplatin 2844.40 アルツモマブ altumomab 2844.40 塩化セシウム(131Cs) cesium (131 Cs) chloride 2844.40 クロルメロドリン(197Hg) chlormerodrin (197 Hg) 2844.40 シアノコバラミン(57Co) cyanocobalamin (57 Co) 2844.40 シアノコバラミン(58Co) cyanocobalamin (58 Co) 2844.40 シアノコバラミン(60Co) cyanocobalamin (60 Co) 2844.40 エチオダイズド油(131I) ethiodized oil (131 I) 2844.40 くえん酸第二鉄(59Fe)注射液 ferric (59 Fe) citrate in 2844.40 フィブリノゲン(125I) fibrinogen (125 I) 2844.40 フルデオキシグルコー ス(18F) fludeoxyglucose ( 18 F) 2844.40 フルオロドパ(18F) fluorodopa (18 F) 2844.40 くえん酸ガリウム(67Ga) gallium (67 Ga) citrate 2844.40 金コロイド(198Au) gold (198 Au), colloidal 2844.40 イオベングアン(131I) iobenguane (131 I) 2844.40 よう化人血清アルブミン(125I) iodinated (125 I) human serum albumin 2844.40 よう化人血清アルブミン(131I) iodinated
  • Pharmacy and Poisons Act 1979

    Pharmacy and Poisons Act 1979

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
  • Quality Issues in Caring for Older People

    Quality Issues in Caring for Older People

    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
  • Antihistamine Therapy in Allergic Rhinitis

    Antihistamine Therapy in Allergic Rhinitis

    CLINICAL REVIEW Antihistamine Therapy in Allergic Rhinitis Paul R. Tarnasky, MD, and Paul P. Van Arsdel, Jr, MD Seattle, Washington Allergic rhinitis is a common disorder that is associated with a high incidence of mor­ bidity and considerable costs. The symptoms of allergic rhinitis are primarily depen­ dent upon the tissue effects of histamine. Antihistamines are the mainstay of therapy for allergic rhinitis. Recently, a second generation of antihistamines has become available. These agents lack the adverse effect of sedation, which is commonly associated with older antihistamines. Current practice of antihistamine therapy in allergic rhinitis often involves random selection among the various agents. Based upon the available clinical trials, chlorpheniramine appears to be the most reasonable initial antihistaminic agent. A nonsedating antihis­ tamine should be used initially if a patient is involved in activities where drowsiness is dangerous. In this comprehensive review of allergic rhinitis and its treatment, the cur­ rent as well as future options in antihistamine pharmacotherapy are emphasized. J Fam Pract 1990; 30:71-80. llergic rhinitis is a common condition afflicting some­ defined by the period of exposure to those agents to which A where between 15 and 30 million people in the United a patient is sensitive. Allergens in seasonal allergic rhinitis States.1-3 The prevalence of disease among adolescents is consist of pollens from nonflowering plants such as trees, estimated to be 20% to 30%. Two thirds of the adult grasses, and weeds. These pollens generally create symp­ allergic rhinitis patients are under 30 years of age.4-6 Con­ toms in early spring, late spring through early summer, sequently, considerable costs are incurred in days lost and fall, respectively.